The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

about

The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.

Item

http://www.wikidata.org/entity/Q48371869

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

The FLT3 and PDGFR inhibitor c ...... cally relevant concentrations.

@en

The FLT3 and PDGFR inhibitor c ...... cally relevant concentrations.

@nl

type

Item

label

The FLT3 and PDGFR inhibitor c ...... cally relevant concentrations.

@en

The FLT3 and PDGFR inhibitor c ...... cally relevant concentrations.

@nl

prefLabel

The FLT3 and PDGFR inhibitor c ...... cally relevant concentrations.

@en

The FLT3 and PDGFR inhibitor c ...... cally relevant concentrations.

@nl

P1476

The FLT3 and PDGFR inhibitor c ...... cally relevant concentrations.

@en

P2093

Karthika Natarajan

http://www.w3.org/2001/XMLSchema#string

Kshama A Doshi

http://www.w3.org/2001/XMLSchema#string

Maria R Baer

http://www.w3.org/2001/XMLSchema#string

Suneet Shukla

http://www.w3.org/2001/XMLSchema#string

Suresh V Ambudkar

http://www.w3.org/2001/XMLSchema#string

Trevor J Mathias

http://www.w3.org/2001/XMLSchema#string

Zeba N Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference

The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions

P2888

s10637-015-0205-y

P304

300-309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-015-0205-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25597754

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

multiple drug resistance